Abstract
Pleuroparenchymal fibroelastosis (PPFE) is a clinicopathologic entity characterized by clinical presentation suggestive of a chronic idiopathic interstitial pneumonia, radiologic features of pleural and parenchymal involvement accentuated in the upper lobes, and a constellation of histologic findings including visceral pleural fibrosis and prominent fibroelastosis of the subpleural lung parenchyma. While the large majority of cases of PPFE have been considered idiopathic, development of PPFE in post-bone marrow transplant patients and in lung transplant recipients has recently been reported. Further, with the growing number of idiopathic PPFE cases reported in the literature, interesting patterns of association between PPFE and various clinical conditions – including prior treatment for malignancy, autoimmunity, recurrent infections, and vascular compromise/ischemia – are beginning to emerge. These associations, reviewed here, may offer clues into the pathogenesis of this rare condition.
Keywords: Chronic lung allograft dysfunction, graft versus host disease, interstitial lung disease, pleuroparenchymal fibroelastosis, pulmonary fibrosis, pulmonary upper lobe fibrosis, restrictive allograft syndrome.
Current Respiratory Medicine Reviews
Title:Pleuroparenchymal Fibroelastosis: Associations and Underlying Conditions
Volume: 9 Issue: 4
Author(s): Farnoosh Tayyari, Tae-Bong Chung and David M. Hwang
Affiliation:
Keywords: Chronic lung allograft dysfunction, graft versus host disease, interstitial lung disease, pleuroparenchymal fibroelastosis, pulmonary fibrosis, pulmonary upper lobe fibrosis, restrictive allograft syndrome.
Abstract: Pleuroparenchymal fibroelastosis (PPFE) is a clinicopathologic entity characterized by clinical presentation suggestive of a chronic idiopathic interstitial pneumonia, radiologic features of pleural and parenchymal involvement accentuated in the upper lobes, and a constellation of histologic findings including visceral pleural fibrosis and prominent fibroelastosis of the subpleural lung parenchyma. While the large majority of cases of PPFE have been considered idiopathic, development of PPFE in post-bone marrow transplant patients and in lung transplant recipients has recently been reported. Further, with the growing number of idiopathic PPFE cases reported in the literature, interesting patterns of association between PPFE and various clinical conditions – including prior treatment for malignancy, autoimmunity, recurrent infections, and vascular compromise/ischemia – are beginning to emerge. These associations, reviewed here, may offer clues into the pathogenesis of this rare condition.
Export Options
About this article
Cite this article as:
Tayyari Farnoosh, Chung Tae-Bong and Hwang M. David, Pleuroparenchymal Fibroelastosis: Associations and Underlying Conditions, Current Respiratory Medicine Reviews 2013; 9 (4) . https://dx.doi.org/10.2174/1573398X113096660024
DOI https://dx.doi.org/10.2174/1573398X113096660024 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Smac-Derived Aza-Peptide As an Aminopeptidase-Resistant XIAP BIR3 Antagonist
Protein & Peptide Letters Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem
Current Drug Targets Phenotypic Alteration of Bone Marrow HSC and Microenvironmental Association in Experimentally Induced Leukemia
Current Stem Cell Research & Therapy Wnt Signaling and Prostate Cancer
Current Drug Targets Pharmacologic Ovarian Preservation in Young Women Undergoing Chemotherapy
Current Medicinal Chemistry Diagnosis and Management of Lynch Syndrome
Recent Patents on Regenerative Medicine sFRP1 Expression Regulates Wnt Signaling in Chronic Myeloid Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry Editorial [Hot Topic:Anti-Inflammatory Strategy: Old Ally or New Promise in Therapy (Guest Editor: Marcella Reale)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Ricin and Saporin: Plant Enzymes for the Research and the Clinics
Current Chemical Biology Editorial [Hot Topic: New Treatment Strategy of the Myelodysplastic Syndromes]
Current Pharmaceutical Design Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Targeting miR-21 Induces Autophagy and Chemosensitivity of Leukemia Cells
Current Drug Targets Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Monoclonal Antibody Therapies Targeting Pancreatic Ductal Adenocarcinoma
Current Drug Discovery Technologies Regulation of Glycolytic and Mitochondrial Metabolism by Ras
Current Pharmaceutical Biotechnology Anti-CD20 in Targeting B Lymphocytes for the Treatment of Autoimmune Diseases: Clinical Benefits and Insights into the Role of B Lymphocytes in Pathophysiology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Targeting the BH3 Domain of Bcl-2 Family Proteins. A Brief History From Natural Products to Foldamers As Promising Cancer Therapeutic Avenues
Current Medicinal Chemistry Paclitaxel (Taxol) and Taxoid Derivates for Lung Cancer Treatment: Potential for Aerosol Delivery
Current Cancer Drug Targets Proteomic Analysis of Liver Preservation Solutions Prior to Liver Transplantation
Current Proteomics